Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812390 · ClinicalTrials.gov registry record · Phase 2
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
A Phase 2 study of Cirrhosis and Ascites Hepatic, sponsored by Anahita Rabiee MD MHS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06812390 is a Phase 2 study of Cirrhosis and Ascites Hepatic that is actively recruiting participants, run by Anahita Rabiee MD MHS. The registered enrollment target is 20 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06812390, a Phase 2 study of Cirrhosis and Ascites Hepatic, is actively recruiting participants, sponsored by Anahita Rabiee MD MHS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
Conditions Studied
Interventions
- DRUG Normal Saline (0.9% NaCl)
- DRUG Albumin infusion (25% albumin)
Study Locations (1)
Connecticut
- West Haven VA Medical Center - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812390
The ClinicalTrials.gov registry entry for NCT06812390 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Anahita Rabiee MD MHS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline (0.9% NaCl) is the first listed.
NCT06812390 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06812390 about?
NCT06812390 is a clinical study titled "Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites". A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
What is the current status of trial NCT06812390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-28. Estimated completion is 2027-03.
What conditions does trial NCT06812390 study?
This clinical trial studies the following conditions: Cirrhosis, Ascites Hepatic.
What interventions are being tested in trial NCT06812390?
The interventions under investigation include: Normal Saline (0.9% NaCl) (DRUG), Albumin infusion (25% albumin) (DRUG).
Who is sponsoring clinical trial NCT06812390?
This trial is sponsored by Anahita Rabiee MD MHS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812390 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.